Teligent, a New Jersey-based specialty generic pharma company, has opened a pharmaceutical product development laboratory in Estonia. The GMP-compliant lab will support the development of topical and injectable pharmaceutical products for the company’s North American markets.

The 3,000-square foot facility also includes administrative space for quality assurance and supply chain employees who oversee the company’s third-party contract manufacturing activities around the world.

“We are excited to strengthen our R&D capabilities through the opening of this product development lab in Estonia,” said Jason Grenfell-Gardner, president and chief executive officer, Teligent. “We are impressed by the caliber of scientific talent available in the country, and look forward to this lab working closely with our R&D colleagues in New Jersey.”

The company established its operation in Estonia in 2015, where it has been managing logistics and supply relationships between third-party suppliers and the U.S. and Canadian markets.